Statins augment efficacy of EGFR-TKIs in patients with
advanced-stage non-small cell lung cancer harbouring KRAS
mutation

J 2015

Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation

FIALA, Ondrej; Milos PESEK; Jindrich FÍNEK; Marek MINARIK; Lucie BENESOVA et al.

Základní údaje

Originální název

Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation

Autoři

FIALA, Ondrej; Milos PESEK; Jindrich FÍNEK; Marek MINARIK; Lucie BENESOVA; Zbyněk BORTLÍČEK a Ondrej TOPOLCAN

Vydání

Tumor Biology, Dordrecht, Springer, 2015, 1010-4283

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.926

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00083938

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Statin; KRAS; Lung cancer; NSCLC; EGFR-TKI; Erlotinib; Gefitinib

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 22. 9. 2015 15:56, Soňa Böhmová

Anotace

V originále

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) represent novel effective agents approved for the treatment of patients with advanced-stage NSCLC. KRAS mutations have been reported as a negative prognostic and predictive factor in patients with NSCLC treated with EGFR-TKIs. Several studies have recently shown that statins can block tumour cell growth, invasion and metastatic potential. We analysed clinical data of 67 patients with locally advanced (IIIB) or metastatic stage (IV) NSCLC harbouring Kirsten rat sarcoma viral oncogene (KRAS) mutation treated with erlotinib or gefitinib. Twelve patients were treated with combination of EGFR-TKI and statin and 55 patients were treated with EGFR-TKI alone. Comparison of patients' survival (progression-free survival (PFS) and overall survival (OS)) according to the treatment used was performed using the Gehan-Wilcoxon test. The median of PFS and OS for patients treated with EGFR-TKI alone was 1.0 and 5.4 months compared to 2.0 and 14.0 months for patients treated with combination of EGFR-TKI and statin (p = 0.025, p = 0.130). In conclusion, the study results suggest significant improvement of PFS for patients treated with combination of statin and EGFR-TKI, and the difference in OS was not significant.

Citovat

FIALA, Ondrej; Milos PESEK; Jindrich FÍNEK; Marek MINARIK; Lucie BENESOVA; Zbyněk BORTLÍČEK a Ondrej TOPOLCAN. Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation. Tumor Biology. Dordrecht: Springer, 2015, roč. 36, č. 8, s. 5801-5805. ISSN 1010-4283. Dostupné z: https://doi.org/10.1007/s13277-015-3249-x.

@article{1311839,
   author = {Fiala, Ondrej and Pesek, Milos and Fínek, Jindrich and Minarik, Marek and Benesova, Lucie and Bortlíček, Zbyněk and Topolcan, Ondrej},
   article_location = {Dordrecht},
   article_number = {8},
   doi = {https://doi.org/10.1007/s13277-015-3249-x},
   keywords = {Statin; KRAS; Lung cancer; NSCLC; EGFR-TKI; Erlotinib; Gefitinib},
   language = {eng},
   issn = {1010-4283},
   journal = {Tumor Biology},
   title = {Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation},
   volume = {36},
   year = {2015}
}

TY  - JOUR
ID  - 1311839
AU  - Fiala, Ondrej - Pesek, Milos - Fínek, Jindrich - Minarik, Marek - Benesova, Lucie - Bortlíček, Zbyněk - Topolcan, Ondrej
PY  - 2015
TI  - Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation
JF  - Tumor Biology
VL  - 36
IS  - 8
SP  - 5801-5805
EP  - 5801-5805
PB  - Springer
SN  - 10104283
KW  - Statin
KW  - KRAS
KW  - Lung cancer
KW  - NSCLC
KW  - EGFR-TKI
KW  - Erlotinib
KW  - Gefitinib
N2  - Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) represent novel effective agents approved for the treatment of patients with advanced-stage NSCLC. KRAS mutations have been reported as a negative prognostic and predictive factor in patients with NSCLC treated with EGFR-TKIs. Several studies have recently shown that statins can block tumour cell growth, invasion and metastatic potential. We analysed clinical data of 67 patients with locally advanced (IIIB) or metastatic stage (IV) NSCLC harbouring Kirsten rat sarcoma viral oncogene (KRAS) mutation treated with erlotinib or gefitinib. Twelve patients were treated with combination of EGFR-TKI and statin and 55 patients were treated with EGFR-TKI alone. Comparison of patients' survival (progression-free survival (PFS) and overall survival (OS)) according to the treatment used was performed using the Gehan-Wilcoxon test. The median of PFS and OS for patients treated with EGFR-TKI alone was 1.0 and 5.4 months compared to 2.0 and 14.0 months for patients treated with combination of EGFR-TKI and statin (p = 0.025, p = 0.130). In conclusion, the study results suggest significant improvement of PFS for patients treated with combination of statin and EGFR-TKI, and the difference in OS was not significant.
ER  -

FIALA, Ondrej; Milos PESEK; Jindrich FÍNEK; Marek MINARIK; Lucie BENESOVA; Zbyněk BORTLÍČEK a Ondrej TOPOLCAN. Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation. \textit{Tumor Biology}. Dordrecht: Springer, 2015, roč.~36, č.~8, s.~5801-5805. ISSN~1010-4283. Dostupné z: https://doi.org/10.1007/s13277-015-3249-x.

Přehled o publikaci